Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Genomics
Scientists announce breakthrough in pathway engineering
September 5th, 2004
Scientists from SLAC (Stanford Linear Accelerator Center) and Genencor International, Inc., (GCOR) announced a breakthrough in the ability to compute, in record time, all possible metabolic behaviors open to a micro-organism. "This development will allow us to reverse engineer a micro-organism to create the product of choice," said Michael V. Arbige, Genencor's senior vice president, technology. "We can go from a small target molecule back to the pathway and then back to the gene. The algorithm will mine the public genomes so we have a list of gene sequences to assemble the cell factory to express the target molecule. This important advancement industrializes the...
Source: Medical Letter on the CDC & FDA (2004-09-05)
|
